The Canadian Adverse Drug Reaction Monitoring Program has been renamed as Canada Vigilance.

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1184, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adverse drug reaction monitoring in Jena

By Hippius Marion   Buchardt Christiane   Farker Katrin   Kuhn Urs Dieter   Reimann Ilselore R   Hoffmann Annemarie  

Experimental and Toxicologic Pathology, Vol. 54, Iss. 5-6, 2003-05 ,pp. : 417-421

Urban & Fischer

Access to resources Recommend Favorite

An Overview of Adverse Drug Reaction Monitoring in China

By Zhou Yibing  

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 2, 2006-01 ,pp. : 79-85

Adis International

Access to resources Recommend Favorite

Growing support for the Canada Vigilance Program

By  

Reactions Weekly, Vol. 1, Iss. 1299, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The Adverse Drug Reactions Advisory Committee (ADRAC) has received 130 adverse drug reaction reports involving reboxetine

By  

Reactions Weekly, Vol. 1, Iss. 1055, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Estradiol/norethisterone has been approved by Health Canada

By  

Inpharma, Vol. 1, Iss. 1644, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite